Cingulate publishes phase 3 ADHD drug trial results in peer-reviewed journal

July 30, 2026 8:30 AM

Cingulate Inc. (NASDAQ: CING) announced that Phase 3 clinical trial results for its lead drug candidate, CTx-1301 (dexmethylphenidate HCl), have ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found